Actinogen Medical Limited ((ATGGF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actinogen Medical Limited is conducting a clinical study titled ‘A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer’s Disease.’ The study aims to evaluate the safety, tolerability, and efficacy of Xanamem, a drug developed for early stages of Alzheimer’s Disease and Major Depressive Disorder, in patients with mild or moderate dementia due to Alzheimer’s Disease.
The intervention being tested is Xanamem, administered as a 10 mg tablet taken once daily. Xanamem is designed to treat symptoms associated with early Alzheimer’s Disease and Major Depressive Disorder by potentially improving cognitive function.
The study is interventional, with participants randomly assigned to receive either Xanamem or a placebo in a parallel-group model. It employs a quadruple masking technique, meaning participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment.
The study began on October 23, 2023, and is currently recruiting participants. The primary completion and estimated completion dates are yet to be disclosed. The last update was submitted on May 21, 2025, indicating ongoing progress and adjustments in the study.
This study update could influence Actinogen Medical’s stock performance positively if results show promise, as it addresses a significant market need in Alzheimer’s treatment. Investors should consider the competitive landscape, as advancements in Alzheimer’s treatment are highly sought after, potentially impacting investor sentiment and market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.